Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0RK1O
|
|||
| Drug Name |
ARO-ANG3
|
|||
| Drug Type |
RNA interference
|
|||
| Indication | Dyslipidemia [ICD-11: 5C80-5C81] | Phase 2 | [1] | |
| Company |
Arrowhead Pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | ANGPTL3 messenger RNA (ANGPTL3 mRNA) | Target Info | Inhibitor | [2] |
| Pathway Interaction Database | Integrins in angiogenesis | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04832971) A Double-blind, Placebo-controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-ANG3 in Adults With Mixed Dyslipidemia. U.S.National Institutes of Health. | |||
| REF 2 | ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets. Curr Atheroscler Rep. 2021 Mar 10;23(5):20. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.